ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
D

Modulation of p53 with the MDM2 Antagonist Idasanutlin, in Combination with Nilotinib Treatment, Targets Primitive CML Cells in Vitro and in Vivo

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING David Vetrie
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING David Vetrie
13 views
January 2, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Scientific Session 5: Mechanisms of Resistance and New Targets
15:26
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

A Genome-scale CRISPR Knock-out Screen in Chronic Myeloid Leukemia I…

Feat. M. Lewis
13:48
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Single-molecule Sequencing Reveals Patterns of Pre-existing Drug Res…

Feat. J. Pritchard
12:49
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Modulation of p53 with the MDM2 Antagonist Idasanutlin, in Combinati…

Feat. D. Vetrie